Open Demat
Be a Partner
Samadhan
Install App
Install App

10579

524404

MARKSANS

img img img img
Compare to down-arrow
View down-arrow
Display down-arrow
Studies down-arrow
No Data Available

MARKSANS PHARMA LIMITED Share Price Update

As of the latest trading session, MARKSANS PHARMA LIMITED is trading at ₹201.17, up by ₹2.77 or 1.39% from its previous close. The stock has moved between ₹197.02 and ₹202.00 today. Over the past year, the stock has delivered a return of -8.72%. In the last month, it has returned 15.40%.

MARKSANS PHARMA LIMITED performance

Today’s low Today’s high
₹ 197.02 ₹ 202.00
₹ 198.40
52 week low 52 week high
₹ 155.00 ₹ 270.70
₹ 198.40
Open Price ₹ 200.00
Prev. Close ₹ 198.40
Volume (Shares) 1957920.00
Total traded value ₹ 3884.51
Upper Circuit ₹ 238.08
Lower Circuit ₹ 158.72
info

Investment Returns

Over 1 Month 15.40% Over 3 Months 8.39% Over 6 Months 4.82% Over 1 Year -8.72%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

MARKSANS PHARMA LIMITED fundamentals


  • Market cap (Cr) 8,990.80
  • P/E Ratio (TTM) 37.35
  • Beta 0.97
  • Book Value / share 32.99
  • Return on equity 14.45%
  • EPS (TTM) 5.44
  • Dividend yield 0.39%
  • Net profit/quarter (Cr) 60.91
info icon alternate text
  • Market cap (Cr) 8,999.80
  • P/E Ratio (TTM) 37.35
  • Beta 0.91
  • Book Value / share 32.99
  • Return on equity 14.45%
  • EPS (TTM) 5.44
  • Dividend yield 0.39%
  • Net profit/quarter (Cr) 60.91
info icon alternate text

MARKSANS PHARMA LIMITED Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars DEC 2025 (Values in Cr)
Revenue 339.73
Operating Expense 273.47
Net Profit 60.91
Net Profit Margin (%) 17.92
Earnings Per Share (EPS) 1.34
EBITDA 91.31
Effective Tax Rate (%) 25.81
Particulars SEP 2025 (Values in Cr)
Revenue 320.44
Operating Expense 257.14
Net Profit 99.81
Net Profit Margin (%) 31.14
Earnings Per Share (EPS) 2.20
EBITDA 130.26
Effective Tax Rate (%) 17.85
Particulars JUN 2025 (Values in Cr)
Revenue 319.73
Operating Expense 258.17
Net Profit 48.06
Net Profit Margin (%) 15.03
Earnings Per Share (EPS) 1.06
EBITDA 72.06
Effective Tax Rate (%) 24.41
Particulars MAR 2025 (Values in Cr)
Revenue 299.36
Operating Expense 256.09
Net Profit 37.59
Net Profit Margin (%) 12.55
Earnings Per Share (EPS) 0.83
EBITDA 58.39
Effective Tax Rate (%) 24.66
Particulars DEC 2024 (Values in Cr)
Revenue 311.87
Operating Expense 259.65
Net Profit 55.46
Net Profit Margin (%) 17.78
Earnings Per Share (EPS) 1.22
EBITDA 82.44
Effective Tax Rate (%) 25.77
Particulars MAR 2025 (Values in Cr)
Revenue 1174.37
Operating Expense 996.90
Net Profit 188.27
Net Profit Margin (%) 16.03
Earnings Per Share (EPS) 4.15
EBITDA 273.88
Effective Tax Rate (%) 22.60
Particulars MAR 2024 (Values in Cr)
Revenue 853.27
Operating Expense 743.46
Net Profit 133.76
Net Profit Margin (%) 15.67
Earnings Per Share (EPS) 2.95
EBITDA 202.01
Effective Tax Rate (%) 22.18
Particulars MAR 2023 (Values in Cr)
Revenue 655.20
Operating Expense 583.65
Net Profit 102.87
Net Profit Margin (%) 15.70
Earnings Per Share (EPS) 2.48
EBITDA 152.39
Effective Tax Rate (%) 22.09
Particulars MAR 2022 (Values in Cr)
Revenue 658.29
Operating Expense 566.04
Net Profit 103.99
Net Profit Margin (%) 15.79
Earnings Per Share (EPS) 2.54
EBITDA 155.97
Effective Tax Rate (%) 22.68
Particulars MAR 2021 (Values in Cr)
Revenue 599.55
Operating Expense 506.38
Net Profit 98.38
Net Profit Margin (%) 16.40
Earnings Per Share (EPS) 2.40
EBITDA 144.87
Effective Tax Rate (%) 20.87
Particulars MAR 2025 (Values in Cr)
Book Value / Share 54.44
ROE % 16.89
ROCE % 20.19
Total Debt to Total Equity 0.12
EBITDA Margin 22.84
Particulars MAR 2024 (Values in Cr)
Book Value / Share 45.57
ROE % 16.53
ROCE % 20.78
Total Debt to Total Equity 0.10
EBITDA Margin 23.38
Particulars MAR 2023 (Values in Cr)
Book Value / Share 38.51
ROE % 18.00
ROCE % 21.77
Total Debt to Total Equity 0.08
EBITDA Margin 21.52
Particulars MAR 2022 (Values in Cr)
Book Value / Share 27.10
ROE % 17.89
ROCE % 22.83
Total Debt to Total Equity 0.07
EBITDA Margin 20.17
Particulars MAR 2021 (Values in Cr)
Book Value / Share 21.66
ROE % 31.34
ROCE % 38.77
Total Debt to Total Equity 0.04
EBITDA Margin 25.16
Particulars MAR 2025 (Values in Cr)
Book Value / Share 30.53
ROE % 14.45
ROCE % 18.55
Total Debt to Total Equity 0.01
EBITDA Margin 23.32
Particulars MAR 2024 (Values in Cr)
Book Value / Share 26.98
ROE % 11.46
ROCE % 14.67
Total Debt to Total Equity 0.01
EBITDA Margin 23.67
Particulars MAR 2023 (Values in Cr)
Book Value / Share 24.52
ROE % 10.85
ROCE % 14.11
Total Debt to Total Equity 0.01
EBITDA Margin 23.26
Particulars MAR 2022 (Values in Cr)
Book Value / Share 16.90
ROE % 15.02
ROCE % 19.45
Total Debt to Total Equity 0.02
EBITDA Margin 23.69
Particulars MAR 2021 (Values in Cr)
Book Value / Share 14.65
ROE % 17.29
ROCE % 22.04
Total Debt to Total Equity 0.02
EBITDA Margin 24.16
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 704.20
Total Assets 3239.63
Total Liabilities 3239.63
Total Equity 2489.38
Share Outstanding 45
Price to Book Ratio 7.28
Return on Assets (%) 11.74
Return on Capital (%) 15.15
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 673.57
Total Assets 2680.95
Total Liabilities 2680.95
Total Equity 2085.90
Share Outstanding 45
Price to Book Ratio 5.62
Return on Assets (%) 11.70
Return on Capital (%) 14.83
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 714.96
Total Assets 2190.38
Total Liabilities 2190.38
Total Equity 1765.07
Share Outstanding 45
Price to Book Ratio 2.87
Return on Assets (%) 12.15
Return on Capital (%) 14.74
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 349.26
Total Assets 1640.10
Total Liabilities 1640.10
Total Equity 1222.97
Share Outstanding 40
Price to Book Ratio 2.70
Return on Assets (%) 11.25
Return on Capital (%) 14.6
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 212.18
Total Assets 1228.81
Total Liabilities 1228.81
Total Equity 905.35
Share Outstanding 40
Price to Book Ratio 3.41
Return on Assets (%) 19.20
Return on Capital (%) 25.53
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 268.69
Total Assets 1755.30
Total Liabilities 1755.30
Total Equity 1383.48
Share Outstanding 45
Price to Book Ratio 7.28
Return on Assets (%) 10.72
Return on Capital (%) 13.61
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 312.22
Total Assets 1516.03
Total Liabilities 1516.03
Total Equity 1222.70
Share Outstanding 45
Price to Book Ratio 5.62
Return on Assets (%) 8.82
Return on Capital (%) 10.94
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 440.26
Total Assets 1344.86
Total Liabilities 1344.86
Total Equity 1111.32
Share Outstanding 45
Price to Book Ratio 2.87
Return on Assets (%) 7.64
Return on Capital (%) 9.26
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 224.04
Total Assets 965.60
Total Liabilities 965.60
Total Equity 784.67
Share Outstanding 40
Price to Book Ratio 2.70
Return on Assets (%) 10.76
Return on Capital (%) 13.17
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 105.61
Total Assets 740.69
Total Liabilities 740.69
Total Equity 599.71
Share Outstanding 40
Price to Book Ratio 3.41
Return on Assets (%) 13.28
Return on Capital (%) 16.4
Particulars MAR 2025 (Values in Cr)
Net Income 503.96
Cash from Operations 332.56
Cash from Investing -49.00
Cash from Financing -65.14
Net change in Cash 92.50
Free Cash Flow 505.48
Particulars MAR 2024 (Values in Cr)
Net Income 423.52
Cash from Operations 352.75
Cash from Investing -140.84
Cash from Financing -68.72
Net change in Cash 20.84
Free Cash Flow 561.59
Particulars MAR 2023 (Values in Cr)
Net Income 337.65
Cash from Operations 300.42
Cash from Investing -259.21
Cash from Financing 197.82
Net change in Cash 176.02
Free Cash Flow 354.05
Particulars MAR 2022 (Values in Cr)
Net Income 247.51
Cash from Operations 172.11
Cash from Investing -84.39
Cash from Financing 79.51
Net change in Cash 94.37
Free Cash Flow 218.44
Particulars MAR 2021 (Values in Cr)
Net Income 302.16
Cash from Operations 227.12
Cash from Investing -44.84
Cash from Financing -15.28
Net change in Cash 118.45
Free Cash Flow 273.54
Particulars MAR 2025 (Values in Cr)
Net Income 243.25
Cash from Operations 77.55
Cash from Investing 17.24
Cash from Financing -29.91
Net change in Cash 18.33
Free Cash Flow 197.46
Particulars MAR 2024 (Values in Cr)
Net Income 171.89
Cash from Operations 72.81
Cash from Investing -114.22
Cash from Financing -26.21
Net change in Cash -106.38
Free Cash Flow 228.48
Particulars MAR 2023 (Values in Cr)
Net Income 132.03
Cash from Operations 83.34
Cash from Investing -194.62
Cash from Financing 210.01
Net change in Cash 67.12
Free Cash Flow 118.62
Particulars MAR 2022 (Values in Cr)
Net Income 134.50
Cash from Operations 87.80
Cash from Investing -128.06
Cash from Financing 70.86
Net change in Cash -1.23
Free Cash Flow 110.65
Particulars MAR 2021 (Values in Cr)
Net Income 124.33
Cash from Operations 127.13
Cash from Investing 8.87
Cash from Financing -13.53
Net change in Cash 102.26
Free Cash Flow 148.13
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 31.94 13.83 1.65 244.77 23.12 40.44
BLISS GVS PHARMA LTD 271.25 25.93 2.53 2869.53 114.45 280.20
CIPLA LTD. 1304.70 22.17 3.20 105391.40 1165.55 1672.20
FERMENTA BIOTECH LIMITED 282.15 9.39 2.12 830.40 256.40 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 31.94 30.71 4.45 244.77 23.12 40.44
AMRUTANJAN HEALTH CARE LTD. 543.55 24.36 4.24 1571.44 490.00 789.95
ASTRAZENECA PHARMA INDIA LTD. 8538.85 102.62 26.71 21347.13 7630.00 10653.05
BLISS GVS PHARMA LTD 271.25 36.96 2.59 2869.53 114.45 280.20

MARKSANS PHARMA LIMITED shareholding pattern

Holding
32.78%
43.87%
16.76%
6.57%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

MARKSANS PHARMA LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
198.40 -2.40 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 198.10
  • 26 Days 185.50
  • 10 Days 193.80
  • 50 Days 180.90
  • 12 Days 192.40
  • 100 Days 180.20
  • 20 Days 187.90
  • 200 Days 188.10
201.89 PIVOT
First Support 195.14 First Resistance 210.04 Second Support 186.99 Second Resistance 216.79 Third Support 180.24 Third Resistance 224.94
RSI 65.64 ADX 35.71 MACD 6.84 Williams % R -16.21 Commodity Channel Index (CCI) 142.07
Date 2026-05-11 Week 996057.00 Same Day 1073038.00 Month 589483.00
1 Year 0.97 3 Year 1.13
Over 1 Month
15.40% down
Over 1 Year
-8.72% down
Over 3 Months
8.39% down
Over 3 Years
37.70% down
Over 6 Months
4.82% down
Over 5 Years
20.57% down

MARKSANS PHARMA LIMITED Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
01 Aug 2025 0.8 Final 01 Aug 2025 Equity shares
17 Sep 2024 0.6 Final 17 Sep 2024 Equity shares
07 Jun 2023 0.5 Final 07 Jun 2023 Equity shares
19 Aug 2022 0.25 Final 23 Aug 2022 Equity shares
15 Sep 2021 0.25 Final 17 Sep 2021 Equity shares
22 Sep 2020 0.1 Final 24 Sep 2020 Equity shares
19 Sep 2019 0.05 Final 21 Sep 2019 Equity shares
19 Sep 2018 0.05 Final 22 Sep 2018 Equity shares
19 Sep 2017 0.05 Final 21 Sep 2017 Equity shares
22 Sep 2016 0.12 Final 24 Sep 2016 Equity shares
23 Sep 2015 0.12 Final 26 Sep 2015 Equity shares
18 Sep 2014 0.1 Final 20 Sep 2014 Equity shares
Ex-Date Old FV NEW FV Record Date
11 Mar 2008 10.0 1.0 18 Mar 2008
Dividend date Dividend amount Dividend type Record date Instrument type
01 Aug 2025 0.8 Final 01 Aug 2025 Equity shares
17 Sep 2024 0.6 Final 17 Sep 2024 Equity shares
07 Jun 2023 0.5 Final 07 Jun 2023 Equity shares
19 Aug 2022 0.25 Final 23 Aug 2022 Equity shares
15 Sep 2021 0.25 Final 17 Sep 2021 Equity shares
22 Sep 2020 0.1 Final 24 Sep 2020 Equity shares
19 Sep 2019 0.05 Final 21 Sep 2019 Equity shares
19 Sep 2018 0.05 Final 22 Sep 2018 Equity shares
19 Sep 2017 0.05 Final 21 Sep 2017 Equity shares
22 Sep 2016 0.12 Final 24 Sep 2016 Equity shares
23 Sep 2015 0.12 Final 26 Sep 2015 Equity shares
18 Sep 2014 0.1 Final 20 Sep 2014 Equity shares
Ex-Date Old FV NEW FV Record Date
11 Mar 2008 10.0 1.0 18 Mar 2008

Top Gainers

up-arrow (%)

Top Losers

up-arrow (%)

Marksans Pharma Share Result Highlights

Particulars

Sep 2024 (₹ in Cr)

Jun 2024 (₹ in Cr)

Mar 2024 (₹ in Cr)

Dec 2023 (₹ in Cr)

Sep 2023 (₹ in Cr)

Revenue

308.63

254.53

225.20

241.36

204.67

Operating Expense

263.65

220.38

198.98

208.09

176.10

Net Profit

63.20

32.02

32.99

25.29

31.29

Net Profit Margin (%)

20.47

12.58

14.64

10.47

15.28

Earnings Per Share (₹)

1.39

0.71

0.73

0.56

0.69

EBITDA

83.64

49.42

46.09

43.30

53.23

Effective Tax Rate (%)

17.19

24.30

14.08

26.90

29.68

Key Highlights:

  • Revenue Growth: Revenue grew significantly in Sep 2024 to ₹308.63 Cr from ₹204.67 Cr in Sep 2023.
  • Strong Profit Performance: Net profit increased to ₹63.20 Cr with a 20.47% margin.
  • Earnings Per Share (EPS): The EPS surged to ₹1.39 in Sep 2024.
  • Operating Efficiency: Operating expenses grew slower than revenue, improving margins.
  • The Marksans Pharma share price has shown positive results, reflecting the growth in key financial metrics.

Marksans Pharma Share Annual Reports

Particulars

Mar 2024 (₹ in Cr)

Mar 2023 (₹ in Cr)

Revenue

853.27

732.00

Operating Expense

743.46

650.23

Net Profit

133.76

112.65

Net Profit Margin (%)

15.67

15.39

Earnings Per Share (₹)

2.95

2.50

EBITDA

202.01

180.52

Effective Tax Rate (%)

22.18

20.50

Key Highlights:

  • Revenue Growth: Revenue increased by approximately ₹121.27 Cr from ₹732.00 Cr in FY 2022-23.
  • Profitability: The net profit grew to ₹133.76 Cr in FY 2023-24 with a 15.67% margin.
  • Strong EPS Performance: Earnings per share rose to ₹2.95.
  • Operational Efficiency: EBITDA grew by ₹21.49 Cr, reflecting improved operational efficiency.
  • The annual financial performance has had a positive impact on the Marksans Pharma share price, reflecting steady growth in revenue and profits.

Marksans Pharma Share Dividend

Particulars

Ex-Date

Record Date

Dividend per Share (₹)

07 Jun, 2023

07 Jun, 2023

Dividend Yield (%)

0.5

Equity Shares

Key Highlights:

  • Consistent Payouts: Marksans Pharma has regularly paid dividends, with the latest payout of ₹0.5 per share in June 2023.
  • Shareholder Returns: Dividend yields have been consistent, offering moderate returns to shareholders.
  • Final Dividends: Recent payouts have been final dividends, reflecting the company’s strong profit performance.
  • The dividend payouts complement the overall performance of the Marksans Pharma share price, providing additional value to investors.

Popular FAQs

Who is the CEO of Marksans Pharma Ltd?

Marksans Pharma Ltd is led by Mr. Mark Saldanha, who serves as the Managing Director and Chief Executive Officer of the company. Under his leadership, the company has expanded its presence in the global pharmaceutical market and achieved significant growth in various regions. Mr. Saldanha’s vision has been instrumental in driving the company’s strategic acquisitions, as well as in its research and development initiatives.

 

When was Marksans Pharma established?

Marksans Pharma Ltd was initially incorporated as Tasc Pharmaceuticals Limited in April 1982. Following a Scheme of Amalgamation, the company’s name was changed to Marksans Pharma Ltd on 10th October 2005. The rebranding marked the beginning of the company’s expanded focus on pharmaceutical formulations, and since then, it has become a prominent player in the pharmaceutical sector.

 

What factors influence the Marksans Pharma Share Price?

The Marksans Pharma share price is influenced by several key factors, including:

  • The company’s financial performance, including revenue growth, net profit, and earnings per share (EPS)
  • Acquisitions and R&D activities
  • Strong revenue and profit growth that boosts investor confidence
  • Successful product launches and US FDA approvals
  • Expanding R&D facilities
  • Broader pharmaceutical market trends and regulatory changes
  • Global economic factors impacting stock performance

 

Is Marksans Pharma debt-free?

Marksans Pharma Ltd is not entirely debt-free. However, the company has maintained a manageable level of debt as part of its capital structure. It strategically acquires businesses and invests in research and development to fuel its growth. The debt levels are often monitored to ensure they do not adversely impact the company's financial health. Despite this, the company has successfully maintained profitability and strong cash flow, helping it manage its liabilities efficiently.

 

What is the CAGR of Marksans Pharma Share?

The Marksans Pharma share price has demonstrated a Compound Annual Growth Rate (CAGR) of:

  • 20% over the last 10 years
  • 87% over the last 5 years
  • 72% over the last 3 years
  • 96% over the past year

This impressive growth rate highlights the company’s consistent performance and the market’s positive response to its strategic initiatives, including acquisitions and expanding its product portfolio.

 

How has the Marksans Pharma Share Price performed over the past year?

Over the past year, the Marksans Pharma share price has seen a remarkable increase of 96%. This surge in share price reflects strong financial performance, successful product approvals, and the company's continued expansion in both domestic and international markets. The robust growth in the past year has also been fueled by investor confidence, supported by strategic acquisitions such as Tevapharm India and the company's increasing presence in the global pharmaceutical industry.

MARKSANS PHARMA LIMITED Share Price

Marksans Pharma Limited was formerly incorporated as 'Tasc Pharmaceuticals Limited' in April, 1982. Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited from 10th October, 2005. The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation. The Company's research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai.

In 2004-05, the Company amalgamated with M/s. Marksans Pharma Limited (formerly M/s. Glenmark Laboratories Limited) pursuant to High Court order dated 19th August, 2005. As provided in the approved Scheme of Amalgamation, necessary shares were issued to the shareholders of the M/s. Marksans Pharma Limited (formerly M/s. Glenmark Laboratories Limited).

The Company acquired majority stake in Nova Pharmaceuticals Australasia Private Limited in 2005; further, it acquired two companies, Bell Sons & Company (Druggists) Limited and Relonchem Limited in the UK in 2008. The Company received first ANDA approval in the USA in 2011. It acquired Time-Cap Laboratories Inc. in the US in 2015.

The Company launched the CNS-Cerebella division in FY 2017-18. It launched soft gelatin capsules, a niche category, Launched two products and received CRL for 4 ANDAs for approval with the USFDA.

The Company commissioned a new R&D center at Navi Mumbai, apart from one in Goa in 2019-20. Access Healthcare for Medical Products LLC, a Dubai-based front-marketing and promotion company was acquired in June, 2022.

In 2023-24, Company acquired the business unit of Tevapharm India Private Limited in Verna, Goa as a going concern via slump sale in April, 2023.

Parent organization Indian Private
NSE symbol MARKSANS
Founded 1992
stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Mark Saldanha Chairman & Managing Director
Harshavardhan Panigrahi Company Sec. & Compli. Officer
Sandra Saldanha Whole-time Director
Digant Mahesh Parikh Independent Director
Varddhman Vikramaditya Jain Whole-time Director
Abhinna Sundar Mohanty Independent Director
Sunny Sharma Non Executive Director
Shailaja Vardhan Independent Director
Srinivas Mishra Independent Director
Right Arrow

Similar stocks

Left Arrow
similar-logo SUNPHARMA
0.41%
1853.3 7.60
down-arrow
similar-logo DIVISLAB
3.12%
6851.5 207.50
down-arrow
similar-logo TORNTPHARM
-0.07%
4378.5 -3.39
down-arrow
similar-logo CIPLA
2.75%
1327.9 35.59
down-arrow
similar-logo DRREDDY
1.98%
1295.2 25.19
down-arrow
similar-logo LUPIN
-0.11%
2242.9 -2.50
down-arrow
similar-logo MANKIND
1.15%
2406.3 27.40
down-arrow
similar-logo ZYDUSLIFE
1.23%
942.2 11.54
down-arrow
similar-logo AUROPHARMA
0.65%
1497.9 9.70
down-arrow
similar-logo LAURUSLABS
-0.25%
1264.8 -3.19
down-arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Marksans Pharma Ltd?

Answer Field

Marksans Pharma Ltd share price is for NSE ₹ 201.17 & for BSE ₹ 201.15 as on May 13 2026 10:20 AM.

What is the Market Cap of Marksans Pharma Ltd Share?

Answer Field

The market cap of Marksans Pharma Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on May 13 2026 10:20 AM.

What is the 52 Week High and Low of Marksans Pharma Ltd?

Answer Field

The 52 Week High and Low of Marksans Pharma Ltd for NSE is ₹ 270.70 and ₹ 155.00 and for BSE is ₹ 270.60 and ₹ 156.00.

What is 1 year return for Marksans Pharma Ltd?

Answer Field

The 1 year returns on the stock has been -8.72%.

What is the P/E Ratio of Marksans Pharma Ltd Share?

Answer Field

As on May 13 2026 10:20 AM the price-to-earnings (PE) ratio for Marksans Pharma Ltd share is 37.35.

What is the PB ratio of Marksans Pharma Ltd Share?

Answer Field

As on May 13 2026 10:20 AM, the price-to-book (PB) ratio for Marksans Pharma Ltd share is 32.99.

How to Buy Marksans Pharma Ltd Share?

Answer Field

You can trade in Marksans Pharma Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Marksans Pharma Ltd Share on Bajaj Broking App?

Answer Field

To buy Marksans Pharma Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Marksans Pharma Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

Who is the CEO of Marksans Pharma Ltd?

Answer Field

Marksans Pharma Ltd is led by Mr. Mark Saldanha, who serves as the Managing Director and Chief Executive Officer of the company. Under his leadership, the company has expanded its presence in the global pharmaceutical market and achieved significant growth in various regions. Mr. Saldanha’s vision has been instrumental in driving the company’s strategic acquisitions, as well as in its research and development initiatives.

When was Marksans Pharma established?

Answer Field

Marksans Pharma Ltd was initially incorporated as Tasc Pharmaceuticals Limited in April 1982. Following a Scheme of Amalgamation, the company’s name was changed to Marksans Pharma Ltd on 10th October 2005. The rebranding marked the beginning of the company’s expanded focus on pharmaceutical formulations, and since then, it has become a prominent player in the pharmaceutical sector.

What factors influence the Marksans Pharma Share Price?

Answer Field

The Marksans Pharma share price is influenced by several key factors, including:

  • The company’s financial performance, including revenue growth, net profit, and earnings per share (EPS)
  • Acquisitions and R&D activities
  • Strong revenue and profit growth that boosts investor confidence
  • Successful product launches and US FDA approvals
  • Expanding R&D facilities
  • Broader pharmaceutical market trends and regulatory changes
  • Global economic factors impacting stock performance

Is Marksans Pharma debt-free?

Answer Field

Marksans Pharma Ltd is not entirely debt-free. However, the company has maintained a manageable level of debt as part of its capital structure. It strategically acquires businesses and invests in research and development to fuel its growth. The debt levels are often monitored to ensure they do not adversely impact the company's financial health. Despite this, the company has successfully maintained profitability and strong cash flow, helping it manage its liabilities efficiently.

What is the CAGR of Marksans Pharma Share?

Answer Field

The Marksans Pharma share price has demonstrated a Compound Annual Growth Rate (CAGR) of:

  • 20% over the last 10 years
  • 87% over the last 5 years
  • 72% over the last 3 years
  • 96% over the past year

This impressive growth rate highlights the company’s consistent performance and the market’s positive response to its strategic initiatives, including acquisitions and expanding its product portfolio.

How has the Marksans Pharma Share Price performed over the past year?

Answer Field

Over the past year, the Marksans Pharma share price has seen a remarkable increase of 96%. This surge in share price reflects strong financial performance, successful product approvals, and the company's continued expansion in both domestic and international markets. The robust growth in the past year has also been fueled by investor confidence, supported by strategic acquisitions such as Tevapharm India and the company's increasing presence in the global pharmaceutical industry.

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Products

arrow

Calculators

arrow

Platforms

arrow

Mutual Funds & SIP

arrow

Important Links

arrow

Explore

arrow

Corporate

arrow

Discover

arrow

Popular Stocks

arrow

Indian Indices

arrow

Global Indices

arrow

Sector Wise Stocks

arrow

IPO

arrow

ATTENTION INVESTORS:

“Investments in securities market are subject to market risk, read all the scheme related documents carefully before investing."

"Prevent Unauthorized transactions in your Trading/Demat Account. Update your mobile numbers/email IDs with your stock brokers/Depository Participant. Receive alerts/information of your transaction/all debit and other important transactions in your Trading/ Demat Account directly from Exchange/CDSL/NSDL at the end of the day. Issued in the interest of investors."

" We collect, retain, and use your contact information for legitimate business purposes only, to contact you and to provide you information & latest updates regarding our products & services."  

"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."

"We understand that certain investment advisors may be approaching members of the public including our clients, representing that they are our partners, or representing that their investment advice is based on our research. Please note that we have not engaged any third parties to render any investment advisory services on our behalf nor are we providing any stock recommendations/tips/research report/advisory. Persons making investments on the basis of such advice may lose all or a part of their investments along with the fee paid to such unscrupulous persons. Please be cautious about any phone call that you may receive from persons representing to be such investment advisors, or a part of research firm offering advice on securities. Do not make payments through e-mail links, WhatsApp or SMS. Please do not share your personal or financial information with any person without proper verification. Always trade through a registered broker."

Bajaj Financial Securities Limited is a subsidiary of Bajaj Finance Limited and is a corporate trading and clearing member of BSE Ltd. and National Stock Exchange of India Ltd. (NSEIL), and also a Depository participant with National Securities Depository Ltd (“NSDL”) and Central Depository Services Ltd. (“CDSL”).

Bajaj Financial Securities Limited is engaged in the business of Stock Broking and as a Depository Participant.Bajaj Financial Securities Limited does not provide any advisory services to its clients. Bajaj Financial Securities Limited may share updates from time to time (through various electronic communication modes) which are sourced from public domain and the same are NOT to be construed as any advice or recommendation from Bajaj Financial Securities Limited. Client is requested to independently evaluate and/or consult their professional advisors before arriving at any conclusion to make any investment. The decision to invest shall be the sole responsibility of the Client and shall not hold Bajaj Financial Securities Limited, its employees and associates responsible for any losses, damages of any type whatsoever.

BSE Ltd. is not in any manner answerable, responsible or liable to any person or persons for any acts of omission or commission, errors, mistakes and/or violation, actual or perceived, by us or our partners, agents, associates etc., of any of the Rules, Regulations, Bye-laws of the Stock Exchange, Mumbai, SEBI Act or any other laws in force from time to time.

BSE Ltd. is not answerable, responsible or liable for any information on this Website or for any services rendered by our employees, our servants, and us.

Personal Loan, Fixed Deposit, EMI Card are provided by Bajaj Finance Limited. Bajaj Financial Securities Limited is only a distributor. These are not exchange traded products and all disputes with respect to the distribution activity, would not have access to exchange investor redressal forum or Arbitration mechanism.

No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.

Please Note:

  1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020

  2. Update your mobile number & email ID with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

  3. Pay 20% upfront margin of the transaction value to trade in cash market segment.

  4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 and BSE vide notice no. 20200731-7 dated July 31, 2020 and 20200831-45 dated August 31, 2020 and other guidelines issued from time to time in this regard.

  5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.

Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do's & Don'ts) in Vernacular Language: BSE | NSE

If the client wishes to revoke /cancel the EDIS mandate placed by them, they can write on email us or call on the toll free number.

Advisory for Investors : NSE | BSE

We also do pro-account trading in Equity & Derivatives Segment.

Filling complaints on SCORES - Easy & Quick

A.  Register on SCORES portal B. Mandatory details for filling complaints on SCORES (i) Name, PAN, Address, Mobile Number, E-mail ID C. Benefits: (i) Effective Communication (ii) Speedy redressal of the grievances.

SEBI Registration No.: INZ000218931 | BSE Cash/CDS/F&O (Member ID: 6706) | NSE Cash/F&O/CDS (Member ID: 90177) | MCX Member ID: 57680 | DP registration No : IN-DP-418-2019 | CDSL DP No.: 12088600 | NSDL DP No. IN304300 | AMFI Registration No.: ARN – 163403 Research Analyst SEBI Registration No. INH000010043

Compliance officer:

Mr. Boudhayan Ghosh 
TEL: 020-48574486
Email for any investor grievances or write to us for DP related matters.

DISCLAIMER

STANDARD DISCLAIMER

Investments in the securities market are subject to market risk, read all related documents carefully before investing.

Reg Office: Bajaj Auto Limited Complex, Mumbai –Pune Road Akurdi Pune 411035. Corporate Office: Bajaj Financial Securities Limited, 1st Floor, Mantri IT Park, Tower B, Unit No 9 & 10, Viman Nagar, Pune, Maharashtra 411014. SEBI Registration No.: INZ000218931 | BSE Cash/F&O/CDS (Member ID:6706) | NSE Cash/F&O/CDS (Member ID: 90177) | MCX Member ID: 57680 | DP registration No: IN-DP-418-2019 | CDSL DP No.: 12088600 | NSDL DP No. IN304300 | AMFI Registration No.: ARN –163403. 

Website: Bajaj Broking

RESEARCH DISCLAIMER

Broking services offered by Bajaj Financial Securities Limited | Registered Office: Bajaj Auto Limited Complex , Mumbai –Pune Road Akurdi Pune 411035 | Corporate Office: Bajaj Financial Securities Limited, 1st Floor, Mantri IT Park, Tower B, Unit No 9 & 10, Viman Nagar, Pune, Maharashtra 411014 | CIN: U67120PN2010PLC136026 | Research Analyst SEB I Registration No: INH000010043.

Details of Compliance Officer: 

Mr. Boudhayan Ghosh (For Broking/DP/Research)
Email | Contact No.: 020-4857 4486 

Investment in the securities involves risks, investor should consult his own advisors/consultant to determine the merits and risks of investment.

DISCLOSURES

Disclosures under the provisions of SEBI (Research Analysts) Regulations 2014 (Regulations) 

Bajaj Financial Securities Limited ("Bajaj Broking" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. There were no instances of non-compliance by Bajaj Financial Securities Limited on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. This research report has been prepared and distributed byBajaj Financial Securities Limited in the capacity of a Research Analyst as per Regulation 22(1) of SEBI (Research Analysts) Regulations 2014 having SEBI Registration No. INH000010043. 

DISCLAIMER

This e-mail/ short message service (SMS) may contain confidential, proprietary or legally privileged information. It should not be used by anyone who is not the original intended recipient. If you have erroneously received this message, please delete it immediately and notify the sender. The recipient acknowledges thatBajaj Financial Securities Limited or its holding and/or associated companies, as the case may be, are unable to exercise control or ensure or guarantee the integrity of/over the contents of the information contained in e-mail /SMS transmissions and further acknowledges that any views expressed in this message are those of the individual sender and no binding nature of the message shall be implied or assumed unless the sender does so expressly with due authority of Bajaj Financial Securities Limited. This message is not intended as an offer or publication or solicitation for distribution for subscription of or purchase or sale of any securities or financial instrument(s) to anyone in whose jurisdiction such subscription etc. requires prior local regulatory clearance or is contrary to the local laws of the land in any manner or as an official confirmation of any transaction. Before opening any attachments, please check them for viruses and defects. 

This service / information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose unless otherwise expressly authorised. This service / information is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subjectBajaj Financial Securities Limited and affiliates/ group/holding companies to any registration or licensing requirements within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and persons in whose possession this document comes, should inform themselves about and observe any such restrictions.  

The data would be provided to the clients on an "as is" and "where-is" basis, without any warranty. Bajaj Financial Securities Limited or its subsidiaries and associated companies shall not be liable for any delay or any other interruption which may occur in providing the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the Bajaj Financial Securities Limited or its subsidiaries and associated companies to provide the data. In no event shall the Bajaj Financial Securities Limited or its holding and associated companies be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data provided by the Bajaj Financial Securities Limited or its holding and associated companies.

ADDITIONAL DISCLAIMER FOR U.S. PERSONS

Bajaj Financial Securities Limited is not a registered broker-dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition, Bajaj Financial Securities Limited is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by Bajaj Financial Securities Limited, including the products and services described herein are not available to or intended for U.S. persons. This email message does not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services and/or shall not be considered as an advertisement tool. "U.S. Persons" are generally defined as a natural person, residing in the United States or any entity organized or incorporated under the laws of the United States. US Citizens living abroad may also be deemed "US Persons" under certain rules.  

ADDITIONAL DISCLAIMER FOR CANADIAN PERSONS

Bajaj Financial Securities Limited is not a registered adviser or dealer under applicable Canadian securities laws nor has it obtained an exemption from the adviser and/or dealer registration requirements under such law. Accordingly, any brokerage and investment services provided by Bajaj Financial Securities Limited, including the products and services described herein are not available to or intended for Canadian persons.  

This mailer and its respective contents do not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services.  

DISCLAIMER FOR REPORT

DISCLOSURES UNDER THE PROVISIONS OF SEBI (RESEARCH ANALYSTS) REGULATIONS 2014 (REGULATIONS)

Bajaj Financial Securities Limited ("Bajaj Broking" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities.  

This Report has been prepared by Bajaj Financial Securities Limited in the capacity of a Research Analyst having SEBI Registration No. INH000010043 and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors.  

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Bajaj Financial Securities Limited and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. Bajaj Financial Securities Limited reserves the right to make modifications and alterations to this statement as may be required from time to time. Bajaj Financial Securities Limited or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Bajaj Financial Securities Limited is committed to providing independent and transparent recommendation to its clients. Neither Bajaj Financial Securities Limited nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance .The disclosures of interest statements incorporated in this report are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The information provided in these reports remains, unless otherwise stated, the copyright of Bajaj Financial Securities Limited. All layout, design, original artwork, concepts and other Intellectual Properties, remains the property and copyright of Bajaj Financial Securities Limited and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the copyright holders.  

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.  

Bajaj Financial Securities Limited and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company(ies), mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. Bajaj Financial Securities Limited may have proprietary long/short position in the above-mentioned scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with Bajaj Financial Securities Limited.  

Bajaj Financial Securities Limited or its associates may have received compensation from the subject company in the past 12 months. Bajaj Financial Securities Limited or its associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. Bajaj Financial Securities Limited or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. Bajaj Financial Securities Limited or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. Bajaj Financial Securities Limited or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or Bajaj Financial Securities Limited’s associates may have financial interest in the subject company. Bajaj Financial Securities Limited, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.  

Research analyst has served as an officer, director or employee of subject Company: No  

Bajaj Financial Securities Limited has financial interest in the subject companies: No  

Bajaj Financial Securities Limited’s Associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.  

Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No  

Bajaj Financial Securities Limited has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No  

Subject company may have been client during twelve months preceding the date of distribution of the research report.  

There were no instances of non-compliance by Bajaj Financial Securities Limited on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. A graph of daily closing prices of the securities is also available at NSE

ANALYST CERTIFICATION

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.  

RISK DISCLOSURE ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

BROKERAGE DISCLAIMER

All leveraged intraday positions will be squared off on the same day. There is no restriction on the withdrawal of the unutilised margin amount. Brokerage will not exceed the SEBI prescribed limit. Visit : Pricing

MTF 

As subject to the provisions of SEBI Circular CIR/MRD/DP/54/2017 dated June 13, 2017, and the terms and conditions mentioned in the lights and obligations statement issued by the TM (if applicable).  

US INVESTING

International investment is not supervised by any regulatory body in India. Thus, any claim or dispute relating to such investment or enforcement of any agreement/contract /claim will not be under laws and regulations of the recognized stock exchanges and investor protection under Indian Securities Law. The account opening process will be carried out on Vested platform and Bajaj Financial Securities Limited will not have any role in it.  

IPO 

This should not be construed as soliciting investment. Investors’ discretion is required. Kindly consult your financial expert before investing. No need to issue cheques by investors while subscribing to IPO. Investments in securities markets are subject to market risks, read all the related documents carefully before investing.  

SCREENERS 

Screeners is not Exchange-approved products and any disputes related to the same will not be dealt on the Exchange platform. 

SECURITIES 

Securities quoted are exemplary and not recommendatory. 

IPV 

Account would be open after all procedure relating to IPV and client due diligence is completed. 

IMAGES 

The images used are only for representation purpose. Proper due diligence has been done for the images and the image is not of any artist. The same is captured from royalty free sites.

THIRD PARTY PRODUCT DISCLAIMER

Bajaj Financial Securities Limited is a distributor for Non-Broking Products/Services such as Mutual Funds, Mutual Funds SIP, IPO, Bonds, Insurance, PMS, Global Investing, any other third-party products/services. These are not Exchange Traded Products, and we are only acting as distributors. All disputes with respect to the distribution activity, would not have access to SCORES/ODR, Exchange investor redressal forum or Arbitration mechanism. Please refer to the detailed disclaimer for Third-Party Products.

DISCLOSURE TO CLIENTS REGARDING PAYOUT OF FUNDS

As per SEBI circular no. SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2023/84 dated June 08, 2023, Stockbrokers are required to upstream the entire client funds lying with them to the Clearing Corporation. Based on client’s request the funds’ release request must be placed with the Clearing Corporation. Based on the internal process and cut-off timelines of the Clearing Corporation the funds will be released to the Stock Broker. In view of this new process, as specified by the regulatory and the cut-off time of Clearing Corporation/Banks processing the funds, Bajaj Financial Securities Limited cannot commit the exact time for releasing funds payout to its client. Clients are requested to note that, Bajaj Financial Securities Limited will not be responsible for any inconvenience caused to clients due to delay in release of funds payout, including fines, delayed charges, defaults, etc.